UCB (OTCMKTS:UCBJF) Shares Gap Down – Should You Sell?

UCB SA (OTCMKTS:UCBJF) gapped down prior to trading on Thursday . The stock had previously closed at $250.59, but opened at $228.94. UCB shares last traded at $228.94, with a volume of 20 shares.

Analyst Upgrades and Downgrades

UCBJF has been the topic of a number of research reports. Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a report on Monday, August 3rd. Piper Sandler reiterated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

UCB Price Performance

The business has a 50 day simple moving average of $265.32 and a 200 day simple moving average of $286.06. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.

Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders.